CAS 1204313-51-8

Icotinib hydrochloride

Description:

Icotinib hydrochloride is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC) that harbors mutations in the epidermal growth factor receptor (EGFR). As a selective inhibitor, it targets the ATP-binding site of the EGFR, thereby blocking downstream signaling pathways that promote tumor growth and survival. The substance is typically administered orally and has shown efficacy in patients with specific EGFR mutations. Icotinib hydrochloride is characterized by its chemical stability, solubility in water, and a specific molecular structure that facilitates its interaction with the target receptor. Its pharmacokinetic profile includes absorption, distribution, metabolism, and excretion characteristics that are crucial for determining dosing regimens. Common side effects may include gastrointestinal disturbances, skin reactions, and fatigue, which are typical of many targeted therapies. Overall, Icotinib hydrochloride represents a significant advancement in personalized cancer therapy, providing a treatment option for patients with specific genetic profiles.

Synonyms:

• Icotinib (Hydrochloride)

Icotinib (Hydrochloride)

CAS: 1204313-51-8

Formula: C₂₂H₂₂ClN₃O₄

Purity: 95%

Molecular weight: 427.8808

Ref: IN-DA008TGV

Icotinib Hydrochloride

CAS: 1204313-51-8

Icotinib Hydrochloride

Purity: ≥98%

Molecular weight: 427.88g/mol

Ref: 54-BUP10446

Icotinib Hydrochloride

CAS: 1204313-51-8

Formula: C₂₂H₂₁N₃O₄·HCl

Molecular weight: 391.43 36.46

Ref: 4Z-I-136001

Icotinib Hydrochloride

CAS: 1204313-51-8

Purity: 99%

Molecular weight: 427.89

Ref: 10-F979653

Icotinib Hydrochloride

CAS: 1204313-51-8

Icotinib hydrochloride is a drug that inhibits the activity of several signal pathways in cancer cells. It is a potent, selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor beta (PDGF-Rβ) with long-term efficacy. Icotinib hydrochloride has been shown to be effective against lung cancer and colorectal adenocarcinoma. This drug also has not shown any significant side effects in clinical trials, which may be due to its low toxicity.

Formula: C₂₂H₂₂ClN₃O₄

Purity: Min. 95%

Molecular weight: 427.88 g/mol

Ref: 3D-EYB31351

Icotinib Hydrochloride

CAS: 1204313-51-8

Icotinib Hydrochloride, an oral EGFR inhibitor (BPI-2009H), may halt cancer growth by blocking EGFR signaling.

Formula: C₂₂H₂₂ClN₃O₄

Purity: 99.89%

Color and Shape: Solid

Molecular weight: 427.88

Ref: TM-T2307